ALL Fetal Tissue Grants HALTED!

Two binders labeled Applications and Grants on a desk with a calculator and papers

President Trump’s administration has delivered a decisive pro-life victory by banning all NIH funding for research using tissue from aborted babies, finally ending taxpayer complicity in this moral outrage.

Story Highlights

NIH announced comprehensive ban on January 22, 2026, effective immediately for all internal and external research using fetal tissue from elective abortions.
Policy expands 2019 Trump restrictions reversed by Biden, eliminating all federal funding with no exceptions for extramural grants.
Pro-life leaders hail it as a major win aligning taxpayer dollars with American values of life and dignity.
17 projects terminated in 2025; UCSF loses $2 million annual contract; three intramural projects shut down.
Exceptions preserved for tissue from miscarriages and stillbirths, balancing ethics with limited research needs.

Policy Announcement Details

The National Institutes of Health issued the ban on January 22, 2026, prohibiting all internal and external funds from supporting research with human fetal tissue from elective abortions. This applies to the NIH Intramural Research Program, grants, cooperative agreements, and contracts. The move terminates three active intramural projects, allowing researchers to exhaust existing tissue stores before full shutdown. Timing aligns with preparations for the March for Life rally, signaling commitment to pro-life priorities after Biden-era reversals.

Historical Context and Expansion

Trump’s first term imposed restrictions in June 2019, banning intramural fetal tissue research and requiring ethics reviews for external grants. Biden reversed these in April 2021, restoring full access until 2025. September 2025 saw non-renewal of 17 projects on cancers, HIV, and disorders like Gaucher disease. The 2026 policy goes further, enacting a total funding prohibition without ethics board loopholes. This shift prioritizes ethical integrity over past allowances that fueled decades of controversy since fetal tissue use began in the 1930s.

Official Justifications and Impacts

NIH Director Jay Bhattacharya cited scientific evolution, noting declining usage—only 77 projects in Fiscal Year 2024—and the need for rigorous, ethical resource stewardship. Funds from existing grants can shift to alternatives, though guidance remains pending. UCSF’s $2 million annual contract, ongoing since 2013, ends abruptly. Pro-life advocate Marjorie Dannenfelser called it a “major victory” against “experimentation using baby body parts.” This protects unborn dignity and taxpayer conscience from government overreach into moral territory.

Researchers face disruptions, with critics like UCSF Chancellor Sam Hawgood labeling it “politically motivated” and neuroscientist Lawrence Goldstein decrying tissue waste via incineration. Bioethicist Alta Charo accused the policy of favoring symbols over lives. Stem cell expert Tyler Lamb warned of delays in treatments for cancer, Parkinson’s, diabetes, and neurological disorders. Yet declining reliance and advancing alternatives underscore the ban’s alignment with modern science and conservative values rejecting abortion complicity.

Long-term, the policy pressures development of superior research models, potentially boosting U.S. innovation without ethical compromise. Patient communities may see shifts, but historical vaccine successes relied on cell lines, not fresh tissue. Taxpayers gain assurance their dollars support life-affirming science, countering Biden’s fiscal mismanagement and woke overreach. This victory reinforces family values, limited government, and the sanctity of life from conception, delivering on promises to restore American principles.